Drugs / ALG-097558
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06945276 | May → Aug 2025 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT06698549 | Feb → Jul 2025 | COVID-19 | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06568861 | Jan → Jul 2025 | COVID-19 | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05840952 | Jul 2023 → Apr 2024 | COVID-19 | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT04746183 | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-02-23 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) aligos.com ↗
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado. |
| 2024-04-25 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study aligos.com ↗
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting |
| 2022-12-08 | Aligos Therapeutics | Results Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting aligos.com ↗
During his presentation, Dr. Jekle indicated that in biochemical and cellular assays, ALG-097558 demonstrated potent, pan-coronavirus antiviral activity. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-23 | Aligos Therapeutics | Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) aligos.com ↗ |
| 2024-04-25 | Aligos Therapeutics | Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study aligos.com ↗ |
| 2023-10-03 | Aligos Therapeutics | Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558 aligos.com ↗ |
| 2022-12-08 | Aligos Therapeutics | Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting aligos.com ↗ |
| 2022-04-04 | Aligos Therapeutics | Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development aligos.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-097558 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06945276 ↗ |
| Action | Inhibit | “A selective, reversible, and potent inhibitor of the SARS-CoV-2 3CLpro” NCT06945276 ↗ |
| Route | Oral | “Oral doses of ALG-097558 in Healthy Volunteers, up to 20 doses over 10 days” NCT05840952 ↗ |